{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T20:55:09Z","timestamp":1706043309424},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,12,12]],"date-time":"2009-12-12T00:00:00Z","timestamp":1260576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11262-009-0429-z","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T10:44:00Z","timestamp":1260528240000},"page":"155-162","source":"Crossref","is-referenced-by-count":3,"title":["Full-length hepatitis B virus sequences from na\u00efve patients with fluctuation of viral load during ADV monotherapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Yongwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,12]]},"reference":[{"key":"429_CR1","doi-asserted-by":"crossref","unstructured":"A.S.F. Lok, B.J. McMahon, AASLD practice guidelines. Hepatology 50(3):1\u201336 (2009)","DOI":"10.1002\/hep.23296"},{"issue":"Suppl 2","key":"429_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2036.2007.03481.x","volume":"26","author":"WF Leemans","year":"2007","unstructured":"W.F. Leemans, M.J. Ter Borg, R.A. de Man, Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment. Pharmacol. Ther. 26(Suppl 2), 171\u2013182 (2007)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"429_CR3","unstructured":"http:\/\/www.seqvirology.com\/drugresistance.html"},{"key":"429_CR4","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"J Hadziyannis","year":"2005","unstructured":"J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote et al., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352, 2673\u20132681 (2005)","journal-title":"N. Engl. J. Med."},{"key":"429_CR5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","volume":"36","author":"H Yang","year":"2002","unstructured":"H. Yang, C.E. Westland, W.E. Delaney IV, Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60\u00a0weeks. Hepatology 36, 464\u2013473 (2002)","journal-title":"Hepatology"},{"key":"429_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcv.2006.08.021","volume":"37","author":"O Schildgen","year":"2006","unstructured":"O. Schildgen, M. Helm, W. Gerlich, Nonresponse to adefovir: host or virus dependent. J. Clin. Virol. 37, 327\u2013328 (2006)","journal-title":"J. Clin. Virol."},{"key":"429_CR7","unstructured":"C. He\u2032zode, S. Chevaliez, M. Bouvier-Alias et al., Efficacy and safety of adefovir dipivoxil 20\u00a0mg daily in HBeAg-positive patients with lamivudine- resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10\u00a0mg daily. J. Hepatol. 46, 791\u2013796 (2007)"},{"issue":"1","key":"429_CR8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","volume":"44","author":"MD Zeng","year":"2006","unstructured":"M.D. Zeng, Y.M. Mao, G.B. Yao et al., A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 44(1), 108\u2013116 (2006)","journal-title":"Hepatology"},{"key":"429_CR9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1365-2036.2007.03272.x","volume":"25","author":"HL Chan","year":"2007","unstructured":"H.L. Chan, V.W. Wong, C.H. Tse et al., Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment. Pharmacol. Ther. 25, 891\u2013898 (2007)","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl 1","key":"429_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2005-915645","volume":"25","author":"S Locarnini","year":"2005","unstructured":"S. Locarnini, Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25(Suppl 1), 9\u201319 (2005)","journal-title":"Semin. Liver Dis."},{"key":"429_CR11","doi-asserted-by":"crossref","first-page":"654A","DOI":"10.1002\/hep.20388","volume":"40","author":"S Durantel","year":"2004","unstructured":"S. Durantel, B. Werle, D. Durantel et al., Different profiles of response to adefovir dipivoxil, factors that may influence response in patients with chronic Hepatitis B. Hepatology 40, 654A (2004)","journal-title":"Hepatology"},{"issue":"3","key":"429_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-3542(99)00007-8","volume":"41","author":"CJ Oon","year":"1999","unstructured":"C.J. Oon, W.N. Chen, N. Lim et al., Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the \u2018a\u2019 epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res. 41(3), 113\u2013118 (1999)","journal-title":"Antiviral Res."},{"issue":"6","key":"429_CR13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.0902-0063.2003.00097.x","volume":"17","author":"S Beckebaum","year":"2003","unstructured":"S. Beckebaum, M. Malag\u00f3, O. Dirsch et al., Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin. Transplant. 17(6), 554\u2013559 (2003)","journal-title":"Clin. Transplant."},{"issue":"2","key":"429_CR14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2036.2008.03731.x","volume":"28","author":"WS Ayoub","year":"2008","unstructured":"W.S. Ayoub, E.B. Keeffe, Review article: current antiviral therapy of chronic hepatitis B. Aliment. Pharmacol. Ther. 28(2), 167\u2013177 (2008)","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"429_CR15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"ASF Lok","year":"2007","unstructured":"A.S.F. Lok, B.J. McMahon, AASLD practice guidelines chronic hepatitis B. Hepatology 45(2), 507\u2013539 (2007)","journal-title":"Hepatology"},{"key":"429_CR16","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/JVI.69.9.5437-5444.1995","volume":"69","author":"S G\u00fcnther","year":"1995","unstructured":"S. G\u00fcnther, B.C. Li, S. Miska, A novel method for efficient amplification of whole hepatitis B virus genome permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69, 5437\u20135444 (1995)","journal-title":"J. Virol."},{"issue":"3","key":"429_CR17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/jhep.2001.22166","volume":"33","author":"LJ Stuyver","year":"2001","unstructured":"L.J. Stuyver, S.A. Locarnini, A. Lok et al., Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33(3), 751\u2013757 (2001)","journal-title":"Hepatology"},{"key":"429_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2893.2003.00471.x","volume":"11","author":"B Werle","year":"2004","unstructured":"B. Werle, K. Cinquin, P. Marcellin, Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J. Viral Hepat. 11, 74\u201383 (2004)","journal-title":"J. Viral Hepat."},{"key":"429_CR19","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","volume":"132","author":"M Ghany","year":"2007","unstructured":"M. Ghany, T.J. Liang, Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132, 1574\u20131585 (2007)","journal-title":"Gastroenterology"},{"key":"429_CR20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/jhep.2001.23045","volume":"33","author":"C Boni","year":"2001","unstructured":"C. Boni, A. Penna, G.S. Ogg et al., Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33, 963\u2013971 (2001)","journal-title":"Hepatology"},{"issue":"6","key":"429_CR21","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1128\/JVI.71.6.4852-4856.1997","volume":"71","author":"PC Tai","year":"1997","unstructured":"P.C. Tai, D. Bank, G.I. Lin et al., Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J. Virol. 71(6), 4852\u20134856 (1997)","journal-title":"J. Virol."},{"key":"429_CR22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/bbrc.1999.1267","volume":"262","author":"WN Chen","year":"1999","unstructured":"W.N. Chen, J.O. Chong, Mutation \u201cHot Spot\u201d in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 262, 757\u2013761 (1999)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"429_CR23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jhep.2008.09.017","volume":"50","author":"SC Mu","year":"2009","unstructured":"S.C. Mu, Y.M. Lin, G.-M. Jow, Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J. Hepatol. 50, 264\u2013272 (2009)","journal-title":"J. Hepatol."},{"key":"429_CR24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI115280","volume":"88","author":"C Ferrari","year":"1991","unstructured":"C. Ferrari, A. Bertoletti, A. Penna et al., Identification of immunodominant T cell epitopes of the hepatitis virus nucleocapcid antigen. J. Clin. Invest. 88, 214\u2013222 (1991)","journal-title":"J. Clin. Invest."},{"key":"429_CR25","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.4049\/jimmunol.173.9.5863","volume":"173","author":"E Mizukoshi","year":"2004","unstructured":"E. Mizukoshi, J. Sidney, B. Livingston et al., Cellular immune responses to the hepatitis B virus polymerase. J. Immunol. 173, 5863\u20135871 (2004)","journal-title":"J. Immunol."},{"key":"429_CR26","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/S0264-410X(02)00297-9","volume":"20","author":"YK Hwang","year":"2002","unstructured":"Y.K. Hwang, N.K. Kim, J.M. Park, HLA-A2.1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine 20, 3770\u20133777 (2002)","journal-title":"Vaccine"},{"key":"429_CR27","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"C. Boni, P. Fisicaro, C. Valdatta et al., Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215\u20134225 (2007)","journal-title":"J. Virol."},{"key":"429_CR28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/jhep.2001.27220","volume":"34","author":"CJ Liu","year":"2001","unstructured":"C.J. Liu, P.J. Chen, M.Y. Lai et al., Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34, 583\u2013589 (2001)","journal-title":"Hepatology"},{"issue":"5","key":"429_CR29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1053\/jhep.2001.28708","volume":"34","author":"JL Hou","year":"2001","unstructured":"J.L. Hou, Z.H. Wang, J.J. Cheng et al., Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 34(5), 1027\u20131034 (2001)","journal-title":"Hepatology"},{"issue":"3","key":"429_CR30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3346\/jkms.2005.20.3.433","volume":"20","author":"SY Lee","year":"2005","unstructured":"S.Y. Lee, M.S. Choi, D. Lee et al., Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J. Korean Med. Sci. 20(3), 433\u2013437 (2005)","journal-title":"J. Korean Med. Sci."},{"issue":"12","key":"429_CR31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3748\/wjg.15.1530","volume":"15","author":"P Jain","year":"2009","unstructured":"P. Jain, DNA-guided hepatitis B treatment: viral load is insufficient with few exceptions. World J. Gastroenterol. 15(12), 1530\u20131531 (2009)","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"429_CR32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAD.0b013e3283224316","volume":"23","author":"S Amini-Bavil-Olyaee","year":"2009","unstructured":"S. Amini-Bavil-Olyaee, J. Sheldon, T. Lutz et al., Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS 23(2), 268\u2013272 (2009)","journal-title":"AIDS"},{"key":"429_CR33","doi-asserted-by":"crossref","unstructured":"I. Chemin, F. Zoulim, Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 286, 52\u201359 (2009) ( http:\/\/www.sciencedirect.com\/science ).","DOI":"10.1016\/j.canlet.2008.12.003"},{"key":"429_CR34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/342599","volume":"186","author":"C Hannoun","year":"2002","unstructured":"C. Hannoun, K. Krogsgaard, P. Horal et al., Genotype mixtures of hepatitis B virus in patients treated with interferon. J. Infect. Dis. 186, 752\u2013759 (2002)","journal-title":"J. Infect. Dis."}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-009-0429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11262-009-0429-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-009-0429-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T06:09:17Z","timestamp":1590300557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11262-009-0429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,12]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s11262-009-0429-z","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,12]]}}}